Product Description
AK131 is a bi-specific antibody derived from Penpulimab (Akeso's marketed PD-1 antibody ) and AK119 (Akeso's CD73 antibody in the clinical stage). AK131 is effectively bound to human PD-1 and CD73 with high affinity. The interaction between PD-1 and its ligand PD-L1 was blocked by AK131 in the reporter gene assay. In cellular assays, AK131 effectively promoted the secretion of IFN-gamma and IL-2 by T cells in the co-culture of PBMCs and Raji-PDL1 cells. (Sourced from: https://www.akesobio.com/en/media/akeso-news/aacr-131/)
Mechanisms of Action: CD73 Inhibitor, PD-1 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Akeso Pharm
Company Location: Asia Pacific
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06166888 |
AK131-101 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-08-01 |
2024-01-18 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
CTR20233829 |
CTR20233829 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |